Menoufia University

Fenofibrate Adjunct Therapy Shows Promise in Mild to Moderate Ulcerative Colitis

6 months ago

• A clinical trial reveals that fenofibrate, when added to mesalamine, significantly improves clinical outcomes in patients with mild to moderate ulcerative colitis. • The study demonstrates that fenofibrate reduces inflammatory markers such as NLRP3 and fecal calprotectin, while increasing SIRT1 and AMPK levels. • Patients receiving fenofibrate in combination with mesalamine showed higher response and remission rates compared to those treated with mesalamine alone. • The findings suggest fenofibrate as a safe and tolerable adjunct therapy, warranting further investigation for ulcerative colitis treatment.